CHAMGAP
MethodologyVerdictsExplanations (KO)Evidence CheckCitation KitMonitoring

Vitamin C × HbA1c in type 2 diabetes

Select a review item to see its details.
Required evidence, verification status and materials actually read
ItemAVerification statusBReading scopeCReview itemDCurrent findingsEWhy unverifiedFRequired materials and conditionsGFurther research
1 Partly verified Full text not readStored summary read N01 · Efficacy and target populationWhich population with type 2 diabetes does the effect apply to?Required
The stored summary identifies the population as people with type 2 diabetes. Trial-specific diagnoses, ages, baseline HbA1c and settings could not be verified from that summary.
S01 S02 S03
The named target population is verified, but trial-specific conditions needed to establish population alignment are unverified.
Obtain trial-specific diagnoses, ages, baseline HbA1c, disease duration, care settings and inclusion/exclusion criteria
Prespecified stratified comparative trials including populations with different representativeness; first obtain tables of the included trials' characteristics
2 Partly verified Full text not readStored summary read N02 · Ingredient, formulation and routeWhat was actually administered?Required
The stored summary names oral tablets or capsules and states that superiority of a specific formulation has not been established. Each trial's chemical form, combination ingredients and product remain unverified.
S01 S03
The route specified in the claim is verified, but original materials needed to match each trial's formulation and ingredients are insufficient.
Verify the chemical form of vitamin C, single ingredient versus combination, tablet versus capsule, oral route, product and content
Obtain product analyses and manufacturing/content records; superiority of a particular formulation requires a direct comparative trial
3 Partly verified Full text not readStored summary read N03 · Dose and exposureWhich dose is the efficacy question about?Required
The overall review's dose range of 200–3,000 mg/day is preserved. Dose, adherence, diet and baseline vitamin C status in each HbA1c trial remain unverified.
S01 S03
Do not assume that the overall review's range represents identical conditions in the trials contributing to HbA1c.
Distinguish daily prescribed dose, dosing frequency, actual intake, adherence, baseline diet and vitamin C status
Comparative trials with prespecified exposure measurement and adherence tracking; effect-modification analyses by baseline status
4 Unverified Full text not readStored summary read N04 · ComparisonLower than what comparator?Required
The stored review summary does not provide each trial's comparator details or the group order used to calculate effects. The existing explanation describes a between-group mean difference, but original trial and synthesis tables were not checked.
S01 S02 S03
The actual comparison is not established because original descriptions of the comparison were not obtained.
Specify the actual placebo, no-treatment, usual-care or active comparator and fix the group order used to calculate the effect
Trials explicitly describing placebo/no added vitamin C and shared treatment, or original descriptions of existing comparators
5 Unverified Full text not readStored summary read N05 · Concomitant treatmentCan the contribution of added vitamin C be separated?Required
Each group's concomitant diabetes treatment, medication adjustments, diet/exercise and other supplements could not be verified from the stored review summary.
S01 S03
General advice against replacing medication is not an experimental record establishing identical treatment in both groups.
Verify shared diabetes treatment, medication adjustments, diet, exercise, other supplements and changes in both groups
Add-on treatment trials with prespecified records of shared treatment, adjustment rules and rescue treatment
6 Partly verified Full text not readStored summary read N06 · Efficacy study designCan intervention effects be distinguished from chance and confounding?Required (causal efficacy)
The reports are labelled systematic reviews/meta-analyses of RCTs. Randomization, concealment and baseline balance in the original trials are unverified.
S01 S03
Distinguish the existence of a study-design label from a result-specific assessment of bias.
Randomization methods, allocation concealment, baseline balance and result-specific risk-of-bias information from comparative trials
Preregistered comparative trials with appropriate randomization, concealment and result analyses; first obtain the original methods
7 Unverified Full text not readStored summary read N07 · Effect of interest and analysisIs this the effect of assignment or the effect of adhering to treatment?Required
The stored summary records a mean reduction and a WMD. Mixing final values with changes, adjustment, ITT/PP, and parallel/crossover/cluster designs remain unverified.
S01 S03
Do not reinterpret −0.54 as a within-group change.
Distinguish ITT/PP, analysis populations, adjustment variables, final values versus changes, and handling of crossover/cluster designs
Comparative trials or reanalysis materials providing a prespecified analysis plan and necessary correlation, period and cluster information
8 Unverified Full text not readStored summary read N08 · Missing dataWho was lost to follow-up?Required
1,133/1,247 are recorded as outcome-specific synthesis samples for HbA1c. Group-specific allocation/completion/analysis numbers and dropout reasons are not recorded at this location.
S01 S03
Not reported in the stored summary. This does not establish that the full paper failed to report it.
Group-specific numbers allocated, completing follow-up, measured and analysed; reasons for dropout, handling of missing data and sensitivity analyses
Trials tracking dropout causes and follow-up with sensitivity analyses under different assumptions; obtain existing flow diagrams and analysis materials
9 Partly verified Full text not readStored summary read N09 · Measured outcomeAre the HbA1c measurements comparable?Required
HbA1c units in percentage points and cautions about glucose-meter/some assay interference are recorded. Trial-specific HbA1c assays, blinding and interference remain unverified.
S01 S03
A glucose-meter caution is not evidence that the HbA1c results are erroneous.
Verify HbA1c assay methods, units, blood-sampling times, assay interference/red-cell limitations and assessor blinding
Trials reporting assay methods, interference validation and blood-sampling rules; analytical method comparisons where needed
10 Partly verified Full text not readStored summary read N10 · DurationDoes the observation period fit the question?Required
The stored summary describes an overall review range of 2 weeks–1 year, mostly less than 6 months. Durations of the individual trials contributing to HbA1c are unverified.
S01 S03
Do not transfer the overall review's duration range to each individual HbA1c trial.
Record treatment, measurement and follow-up periods separately, with evidence supporting the time frame used to interpret HbA1c changes
Trials scheduling visits based on the outcome's time characteristics; official original assay references supporting duration criteria require follow-up checking
11 Partly verified Full text not readStored summary read N11 · Result definitionExactly what difference was observed?Required
S01 −0.54 percentage points (95% CI −0.90 to −0.17) and S03 WMD −0.51 percentage points (95% CI −0.81 to −0.20) are preserved. S02 restates −0.54.
S01 S02 S03
The stored locations of values and units are verified, but group order, analysis/time points and attribution to original paper tables are unverified.
Link effect estimates, measures, units, group order, confidence intervals, time points, denominators and adjustment to original materials
Obtain original trial result tables/supplements and recheck the original numbers; define the unit of analysis before a new synthesis
12 Partly verified Full text not readStored summary read N12 · Precision and sample sizeWhat conclusions does the interval allow?Required
Outcome-specific HbA1c CIs and samples are available. The stored summary mentions some clinical-relevance thresholds, but contains no verified numerical threshold or source supporting its application.
S01 S03
Precision sufficiency is not judged because no new importance threshold has been invented.
Link outcome-specific samples, variance and effect intervals to a justified important difference
Trials with sample sizes based on important-difference, variance and dropout assumptions; first agree on the threshold and obtain existing variance information
13 Review incomplete Full text not readStored summary read N13 · Selective reportingCan all prespecified results be examined?Required
Bibliographic records in the stored materials mainly concern reviews. Original trial registrations, protocols, SAPs and comparisons of prespecified versus reported HbA1c analyses were not verified from these materials.
S01 S03
Registrations/plans were neither obtained nor searched in this review. Lack of registration or selective reporting is not established.
Compare registration, protocol and analysis plans with reported HbA1c time points, analyses and reasons for changes
Trials publishing preregistration, protocols/SAPs and all results, or retrieval of existing registrations/supplements
14 Unverified Full text not readStored summary read N14 · Study familiesDo three review papers represent independent replication?Required
Bibliographic identities exist for three review reports. The acquired summaries contain no original-trial/related-report family table or review-overlap table.
S01 S02 S03
Do not add original trial counts as 16+18 or participants as 1,133+1,247.
Link original trials, registrations, related reports and review inclusion tables into study families, recording overlap
Obtain included-trial/registration lists and compare duplicates; then conduct independent replication in a different recruited population
15 Partly verified Full text not readStored summary read N15 · Inconsistency and replicationAre results consistent under different conditions?Required (overall applicability)
S03 I²=90.4% is recorded in the stored summary. Trial-specific opposing/no-difference/positive HbA1c values are unverified. Non-significant results and limitations for other outcomes are also preserved in the original record.
S01 S02 S03
Similar directions of two pooled averages do not verify independent replication or consistent effects in individual trials.
Record trial-specific opposing, no-difference and positive results, condition differences, heterogeneity and prespecified subgroups
Independent multicentre replication under standardized conditions; test prespecified hypotheses about baseline status and dose
16 Unverified Full text not readStored summary read N16 · Dose questionIs a higher dose better?Additional (required for dose selection)
The stored summary states that a standard diabetes dose and superiority of particular formulations are undetermined. Direct dose-comparison results could not be verified from the stored summary.
S01 S03
Further searching is needed to establish whether dose studies exist beyond these stored materials.
Direct dose comparisons, exposure/dose response, and joint observation of benefits and harms
Randomized dose comparisons using the same formulation and shared treatment. Determine sample sizes and doses after reviewing the evidence
17 Unverified Full text not readStored summary read N17 · PersistenceDoes the effect persist long term or after stopping treatment?Additional (required for persistence claims)
The limitation that most studies are short term is preserved. Post-treatment persistence, long-term medication changes and fixed extension follow-up results are unverified in the acquired summaries.
S01 S03
A duration range including 1 year does not by itself verify long-term persistence or persistence after stopping treatment.
Verify long-term exposure, post-treatment visits, medication changes and HbA1c trajectories
Comparative trials/follow-up studies with prespecified long-term extensions and post-treatment follow-up. Duration is undetermined
18 Partly verified Full text not readStored summary read N18 · SafetyWhat harms were observed in the same population at the same dose?Required (harm question)
The existing summary records limited safety data and gastrointestinal/oxalate cautions. Group-specific event counts, denominators and durations in this population at these doses are unverified.
S02 S04
Separate general cautions from events observed in trials. Do not record non-reporting as zero events.
Verify group-specific harm definitions, collection methods, event/person counts, denominators, exposure periods and discontinuations
Obtain comparative trials/safety reports documenting both prespecified harm collection and unanticipated harms
19 Unverified Full text not readStored summary read N19 · Long-term/rare harms and special populationsWhat about harms outside short trials and vulnerable populations?Required (applicable harm assessment)
The stored summary cautions about kidney disease/stone histories and iron overload. Long-term exposure and absolute risks in specific populations are unverified in these materials.
S04
The existence of a caution group is not a numerical risk estimate or evidence of no efficacy.
Exposure, comparisons, occurrence and long-term harm data in existing caution groups, including people with kidney disease/stone histories or iron overload
Long-term cohorts/registries with denominators, exposure and appropriate comparators; special-population data require separate searching
20 Unverified Full text not readStored summary read N20 · Applicability to subgroupsIs the effect greater in deficient participants or particular populations?Additional (required for subgroup claims)
The stored summary describes possible differences by low baseline vitamin C, dose and duration. Prespecified subgroup and interaction evidence is unverified.
S01 S03
Do not upgrade a hypothesis to verified efficacy in a particular population.
Baseline vitamin C, HbA1c, medication/disease characteristics, prespecified effect-modification hypotheses and interactions
Prespecified stratified trials or agreed individual-participant-data analyses. Label subgroups not defined in advance as exploratory
21 Review incomplete Full text not readStored summary read N21 · Search, access and publication statusWhat might the current record have missed?Required (claims about the current overall evidence)
The existing evidence cut-off field is 2026-07-24. On 2026-10-04, only stored materials and methodology were checked; no new clinical search or correction/retraction checks were performed.
S01 S02 S03 S04
This case did not review the entire current clinical literature or its latest status. The existence and accessibility of materials beyond papers are also unverified.
Search scope/dates, inclusion/exclusion, registrations/unpublished studies, corrections/retractions, and material-specific access/reading histories
In an authorized follow-up, search and select new literature/registrations/publication-status information and record access. This was not performed here
22 Not applicable Full text not readStored summary read N22 · Clinical outcomes and scope boundariesDoes a change in HbA1c directly establish benefits for complications?Additional (required for extended claims)
The selected question concerns numerical HbA1c change. Existing separate subclaims describe benefits for complications/mortality as unestablished. Those findings were not reassessed here.
S01 S03
Clinical-event trials are not required for the HbA1c question itself. Extending to benefits for complications requires separate conditions.
Questions about complications, quality of life or mortality require separate comparative results, events and durations for those outcomes
Long-term comparative trials based on clinical events, with a separately defined question. This is not a new claim or search in this case
No items match your search or filter.

22 itemsWhat the statuses mean

Assessment scope

Stored-material review date
2026-10-04
Original evidence cut-off
2026-07-24
Scope actually checked
Existing review summaries and the relevant methodology sections. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean
This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population
People with type 2 diabetes; trial-specific age ranges, diagnostic criteria and baseline characteristics are unverified
Ingredient, formulation and route
Assessment scope: oral vitamin C tablets or capsules. The chemical form and whether each trial used a single ingredient or a combination remain unverified
Dose
The overall review covered 200–3,000 mg/day. Doses in the individual HbA1c trials are unverified
Comparator
Required comparison: vitamin C added to shared background treatment versus placebo or no added vitamin C. This defines Chamgap's question; the actual comparators in the original trials are unverified
Measured outcome
Difference in HbA1c versus the comparator, in percentage points. The exact group order, final values versus changes from baseline, and adjustment are unverified
Duration
The overall review covered 2 weeks–1 year, mostly less than 6 months. Trial-specific HbA1c durations and an appropriate minimum duration are unverified or undetermined
Questions outside this scope
Fasting or post-meal glucose, complications or mortality, replacing medication, optimal doses and efficacy in special populations are separate questions

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Mason SA, Keske MA, Wadley GD. Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2021;44(2):618-630. PMID: 33472962. DOI: 10.2337/dc20-1893.

Publisher · PubMed

Material type
Systematic review and meta-analysis of randomized trials with GRADE assessment
Materials actually read
Relevant sections and citation records in the existing review summary were read
Findings recorded in the stored summary
Stored summary: HbA1c analysis of 16 RCTs and 1,133 participants, −0.54 percentage points (95% CI −0.90 to −0.17).
Record level
Values reported in a stored summary, not directly verified against the original paper
Study overlap and independent replication
Unverified; counts of review papers and original trials do not represent the number of independent replications
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
AbstractUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
Full textUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
SupplementUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
ProtocolUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
RegistrationUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
Original dataUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself

S02 · Fong C, Alesi S, Mousa A, et al. Efficacy and Safety of Nutrient Supplements for Glycaemic Control and Insulin Resistance in Type 2 Diabetes: An Umbrella Review and Hierarchical Evidence Synthesis. Nutrients. 2022;14(11):2295. PMID: 35684094. PMCID: PMC9182772. DOI: 10.3390/nu14112295.

Publisher · PMC · PubMed

Material type
Umbrella review and hierarchical evidence synthesis of nutritional-supplement meta-analyses
Materials actually read
Relevant sections and citation records in the existing review summary were read
Findings recorded in the stored summary
Stored summary: restates the HbA1c mean difference of −0.54 percentage points. Not counted as a new independent trial result.
Record level
Values reported in a stored summary, not directly verified against the original paper
Study overlap and independent replication
Unverified; counts of review papers and original trials do not represent the number of independent replications
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
AbstractUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
Full textUnverified (no web access/search attempted in this review)Access not attemptedNot readPMCID PMC9182772 appears in S02's stored bibliographic record. Public full-text availability or successful access was not verified in this review.
SupplementUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
ProtocolUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
RegistrationUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
Original dataUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself

S03 · Nosratabadi S, Ashtary-Larky D, Hosseini F, et al. The effects of vitamin C supplementation on glycemic control in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(8):102824. PMID: 37523928. DOI: 10.1016/j.dsx.2023.102824.

Publisher · PubMed

Material type
Updated systematic review and meta-analysis of randomized trials
Materials actually read
Relevant sections and citation records in the existing review summary were read
Findings recorded in the stored summary
Stored summary: HbA1c analysis of 18 RCTs and 1,247 participants, WMD −0.51 percentage points (95% CI −0.81 to −0.20), I² 90.4%.
Record level
Values reported in a stored summary, not directly verified against the original paper
Study overlap and independent replication
Unverified; counts of review papers and original trials do not represent the number of independent replications
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
AbstractUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
Full textUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
SupplementUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
ProtocolUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
RegistrationUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself
Original dataUnverified (no web access/search attempted in this review)Access not attemptedNot readThe existing review summary was read, rather than the paper itself

S04 · National Institutes of Health, Office of Dietary Supplements. Vitamin C: Fact Sheet for Health Professionals. Updated July 31, 2025. PMID: none. DOI: none.

Official source

Material type
Existing citation record of official safety information
Materials actually read
Only citations and safety guidance in the existing review summary were read
Findings recorded in the stored summary
The existing stored summary records cautions about gastrointestinal effects, oxalate/stones, iron overload and meter interference. These are not event-count/incidence data for this population.
Record level
Preserved general caution information; not a new safety assessment
Study overlap and independent replication
Not applicable: not an efficacy replication trial
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
Full web fact sheetUnverified (original source not accessed in this review)Access not attemptedPreserved citations/summary only

Report counts versus independent study counts

Review inclusion tables and original-trial identities are unverified. S02's restatement and S03's update are not added together as independent populations

Review criteria

Version 1.1 · Criteria record date 2026-10-04. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which population with type 2 diabetes does the effect apply to?
Required materials and conditions
Obtain trial-specific diagnoses, ages, baseline HbA1c, disease duration, care settings and inclusion/exclusion criteria
Conditions for verification
Identify each trial's population, diagnoses and baseline characteristics, and explain matches or differences with the selected claim using locations in the original paper
Requirement and applicability
Required
Application exceptions
For mixed populations, separate results or documentation of the population mix and indirectness are acceptable. Other types of diabetes require a separate question.
Why this condition is needed
The broad label 'type 2 diabetes' does not establish that the target populations are equivalent.
Referenced methods
M03 §3.2.1
N02 · What was actually administered?
Required materials and conditions
Verify the chemical form of vitamin C, single ingredient versus combination, tablet versus capsule, oral route, product and content
Conditions for verification
Verify each trial's actual ingredients, route, formulation and control ingredients, while retaining unverified details as unverified
Requirement and applicability
Required
Application exceptions
Combination products may contribute if shared ingredients and between-group differences can be separated. Intravenous preparations and foods require separate comparisons.
Why this condition is needed
Needed to avoid attributing effects from other formulations, routes or added ingredients to oral vitamin C.
Referenced methods
M03 §3.2.2–3.2.3
N03 · Which dose is the efficacy question about?
Required materials and conditions
Distinguish daily prescribed dose, dosing frequency, actual intake, adherence, baseline diet and vitamin C status
Conditions for verification
Link dose, actual exposure, verification methods and duration for each trial contributing to the HbA1c analysis
Requirement and applicability
Required
Application exceptions
When baseline deficiency information is absent, retain studies of the overall effect and leave only deficiency-specific applicability unverified.
Why this condition is needed
If nominal dose differs from actual exposure, applicability and dose interpretation change.
Referenced methods
M03 §3.2.2; M15 §15.2.4
N04 · Lower than what comparator?
Required materials and conditions
Specify the actual placebo, no-treatment, usual-care or active comparator and fix the group order used to calculate the effect
Conditions for verification
Verify each trial's control conditions, group order and rationale for inclusion in the synthesis
Requirement and applicability
Required
Application exceptions
Retain active-comparator results, but present them separately from the main question comparing against no added vitamin C.
Why this condition is needed
A different comparator means a different question, even when the numerical result is the same.
Referenced methods
M03 §3.2.3
N05 · Can the contribution of added vitamin C be separated?
Required materials and conditions
Verify shared diabetes treatment, medication adjustments, diet, exercise, other supplements and changes in both groups
Conditions for verification
Link baseline and follow-up concomitant treatments/changes, between-group differences and how they were handled
Requirement and applicability
Required
Application exceptions
Do not require completely identical treatment. If treatment changes, review balance, analysis and alignment with the effect of interest.
Why this condition is needed
Check whether differences in other treatments contribute to the observed difference.
Referenced methods
M03 §3.2.3; M08 §8.2.2–8.2.3
N06 · Can intervention effects be distinguished from chance and confounding?
Required materials and conditions
Randomization methods, allocation concealment, baseline balance and result-specific risk-of-bias information from comparative trials
Conditions for verification
Obtain original evidence of the actual design, randomization/concealment and relevant baseline differences, and discuss their effect on results
Requirement and applicability
Required (causal efficacy)
Application exceptions
Also record and use non-randomized studies as supporting evidence. Judgments must fit parallel, crossover or cluster designs. A formal RoB 2 assessment is outside this review's scope.
Why this condition is needed
The label 'randomized' alone does not resolve risk-of-bias concerns.
Referenced methods
M08 §8.1–8.2.3
N07 · Is this the effect of assignment or the effect of adhering to treatment?
Required materials and conditions
Distinguish ITT/PP, analysis populations, adjustment variables, final values versus changes, and handling of crossover/cluster designs
Conditions for verification
Verify agreement or differences between the effect of interest, the actual analysis and the effect used in the synthesis
Requirement and applicability
Required
Application exceptions
Crossover/cluster requirements are marked not applicable or handled separately only after the design is verified.
Why this condition is needed
Needed to avoid combining different effects and analyses as if they were the same result.
Referenced methods
M08 §8.2.2; M15 §15.3.1
N08 · Who was lost to follow-up?
Required materials and conditions
Group-specific numbers allocated, completing follow-up, measured and analysed; reasons for dropout, handling of missing data and sensitivity analyses
Conditions for verification
Link outcome- and time-specific denominators, missingness, handling methods and results under different assumptions
Requirement and applicability
Required
Application exceptions
Do not use an arbitrary universal dropout-rate threshold. Examine causes of missingness and their relationship to the outcome.
Why this condition is needed
Review the possibility that missing data changed the observed result.
Referenced methods
M08 Table 8.2.a
N09 · Are the HbA1c measurements comparable?
Required materials and conditions
Verify HbA1c assay methods, units, blood-sampling times, assay interference/red-cell limitations and assessor blinding
Conditions for verification
Verify each trial's HbA1c methods, units, visits and measurement limitations. Distinguish percentage points from relative percentages
Requirement and applicability
Required
Application exceptions
Do not generalize glucose-meter interference to all HbA1c assays. Review each assay method separately.
Why this condition is needed
Needed to distinguish measurement differences from actual changes.
Referenced methods
M08 Table 8.2.a; M03 §3.2.4
N10 · Does the observation period fit the question?
Required materials and conditions
Record treatment, measurement and follow-up periods separately, with evidence supporting the time frame used to interpret HbA1c changes
Conditions for verification
Specify the timeline of each contributing trial, the questions that timeline can answer and its limitations
Requirement and applicability
Required
Application exceptions
Do not adopt an arbitrary minimum number of weeks. An appropriate duration is undetermined from these materials alone.
Why this condition is needed
Short-term observation and sustained effects are different questions.
Referenced methods
M03 §3.2.2–3.2.4
N11 · Exactly what difference was observed?
Required materials and conditions
Link effect estimates, measures, units, group order, confidence intervals, time points, denominators and adjustment to original materials
Conditions for verification
Make analysis attribution traceable so that distinct results are not mistaken for the same effect
Requirement and applicability
Required
Application exceptions
Retain synthesis summaries as results, while distinguishing them from direct results of original trials.
Why this condition is needed
Within-group changes, between-group differences and pooled estimates are different results.
Referenced methods
M15 §15.3.1–15.3.3
N12 · What conclusions does the interval allow?
Required materials and conditions
Link outcome-specific samples, variance and effect intervals to a justified important difference
Conditions for verification
Compare the effects the CI excludes or allows—important effects, small effects or no difference—with an evidence-based threshold
Requirement and applicability
Required
Application exceptions
If a clinical-importance threshold is absent, leave it undetermined. Do not impose an arbitrary minimum sample or trial count.
Why this condition is needed
Study or participant counts alone cannot establish sufficiency, and statistical significance does not establish efficacy.
Referenced methods
M15 §15.3.1–15.3.3
N13 · Can all prespecified results be examined?
Required materials and conditions
Compare registration, protocol and analysis plans with reported HbA1c time points, analyses and reasons for changes
Conditions for verification
Compare prespecified and reported outcomes, analyses and time points, explaining changes or why comparison is impossible
Requirement and applicability
Required
Application exceptions
Retain the study's existence and results even if registration is absent or private. Do not turn an unverified status into confirmed selective reporting.
Why this condition is needed
Examine whether an analysis was selected because its results were favourable.
Referenced methods
M08 Table 8.2.a; M04 §4.6.3
N14 · Do three review papers represent independent replication?
Required materials and conditions
Link original trials, registrations, related reports and review inclusion tables into study families, recording overlap
Conditions for verification
Trace report → original trial → inclusion in each review, and identify matching or unresolved identities
Requirement and applicability
Required
Application exceptions
Retain unresolved study families under provisional identities. Unique trial and participant counts remain undetermined.
Why this condition is needed
The same participants or trial must not be counted more than once.
Referenced methods
M04 §4.6.1–4.6.2
N15 · Are results consistent under different conditions?
Required materials and conditions
Record trial-specific opposing, no-difference and positive results, condition differences, heterogeneity and prespecified subgroups
Conditions for verification
Preserve the distribution of unique trial results, explanations of condition differences/inconsistency and uncertainty
Requirement and applicability
Required (overall applicability)
Application exceptions
Between-study comparison may be not applicable for a single study family, but NA is not assigned here because study families remain unresolved.
Why this condition is needed
One pooled average does not guarantee results in every population and setting.
Referenced methods
M03 §3.2.1; M15 §15.3.1
N16 · Is a higher dose better?
Required materials and conditions
Direct dose comparisons, exposure/dose response, and joint observation of benefits and harms
Conditions for verification
Dose differences within the same comparison framework, or dose-response evidence explicitly describing confounding limitations
Requirement and applicability
Additional (required for dose selection)
Application exceptions
The main HbA1c-change question can be retained without claiming dose superiority.
Why this condition is needed
Dose differences across trials may be confounded by differences in populations and durations.
Referenced methods
M03 §3.2.2; Chamgap's own dose-study design proposal
N17 · Does the effect persist long term or after stopping treatment?
Required materials and conditions
Verify long-term exposure, post-treatment visits, medication changes and HbA1c trajectories
Conditions for verification
Long-term comparative results with timelines, treatment continuation/discontinuation and loss to follow-up
Requirement and applicability
Additional (required for persistence claims)
Application exceptions
Do not remove short-term studies as ineligible. Leave persistence separately unverified.
Why this condition is needed
A change at the end of treatment differs from a sustained effect.
Referenced methods
M03 §3.2.2; Chamgap's own persistence-study design proposal
N18 · What harms were observed in the same population at the same dose?
Required materials and conditions
Verify group-specific harm definitions, collection methods, event/person counts, denominators, exposure periods and discontinuations
Conditions for verification
Distinguish events in both groups, observation periods, denominators, collection methods and non-reporting
Requirement and applicability
Required (harm question)
Application exceptions
Retain efficacy results even when harms are not reported in an efficacy study. Present safety separately.
Why this condition is needed
Non-reporting cannot be interpreted as zero events or established safety.
Referenced methods
M19 §19.1.2–19.2.4
N19 · What about harms outside short trials and vulnerable populations?
Required materials and conditions
Exposure, comparisons, occurrence and long-term harm data in existing caution groups, including people with kidney disease/stone histories or iron overload
Conditions for verification
Verify design-specific event definitions, exposure, comparisons/confounding, denominators, durations and population-applicability limitations
Requirement and applicability
Required (applicable harm assessment)
Application exceptions
Also preserve observational studies, registries and case signals. Without control of confounding and denominators, do not establish incidence rates or causality.
Why this condition is needed
The restricted populations and durations of efficacy trials may not capture rare harms.
Referenced methods
M19 §19.1.2, §19.2.2–19.2.4
N20 · Is the effect greater in deficient participants or particular populations?
Required materials and conditions
Baseline vitamin C, HbA1c, medication/disease characteristics, prespecified effect-modification hypotheses and interactions
Conditions for verification
Verify prespecified hypotheses and definitions, subgroup samples/estimates, interactions and precision
Requirement and applicability
Additional (required for subgroup claims)
Application exceptions
Pregnancy, children and other types of diabetes are not automatic extensions of this claim.
Why this condition is needed
Needed to avoid extending an overall average to a particular population.
Referenced methods
M03 §3.2.1; Chamgap's own effect-modification proposal
N21 · What might the current record have missed?
Required materials and conditions
Search scope/dates, inclusion/exclusion, registrations/unpublished studies, corrections/retractions, and material-specific access/reading histories
Conditions for verification
Record the scope in which evidence is absent or unverified, by date and material type
Requirement and applicability
Required (claims about the current overall evidence)
Application exceptions
No new clinical search was performed. Only the currently preserved scope applies.
Why this condition is needed
The existence of a stored summary does not mean the entire current literature has been checked.
Referenced methods
M04 §4.5, §4.6.3
N22 · Does a change in HbA1c directly establish benefits for complications?
Required materials and conditions
Questions about complications, quality of life or mortality require separate comparative results, events and durations for those outcomes
Conditions for verification
Identify the separate clinical question/outcome and direct evidence. Do not automatically extend HbA1c findings
Requirement and applicability
Additional (required for extended claims)
Application exceptions
Do not require clinical-event trials as a mandatory condition for the selected question about numerical HbA1c change itself.
Why this condition is needed
A boundary distinguishing questions about biomarkers from questions about clinical events.
Referenced methods
M03 §3.2.4; Chamgap's own boundary for extended claims
Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle
Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations of the intervention.
Extent of review
Relevant sections of the original web text reviewed directly; not an application of the chapter's entire methodology

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle
Distinguish and link studies and reports; do not omit a study solely because an outcome is unreported.
Extent of review
Relevant sections of the original web text reviewed directly; not an application of the chapter's entire methodology

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle
Define the result and effect of interest before examining randomization, deviations, missing data, measurement and selective reporting.
Extent of review
Relevant sections of the original web text reviewed directly; not an application of the chapter's entire methodology

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle
Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review
Relevant sections of the original web text reviewed directly; not an application of the chapter's entire methodology

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle
Harm questions may require different designs, populations and follow-up than efficacy questions. Case reports do not establish incidence rates.
Extent of review
Relevant sections of the original web text reviewed directly; not an application of the chapter's entire methodology
What the statuses mean
Partly verified
Some required conditions were verified in the stored summary. This does not mean all conditions were met
Unverified
Required information/conditions could not be established within this review's scope
Review incomplete
Original-material comparisons/searches within the permitted scope were not performed
Not reported
A scope-limited status meaning that the item was not stated in the particular material/section that was read
Inaccessible
Used only when access was actually attempted and failed. Not assigned to the clinical materials in this review
Insufficient evidence for the conditions
Used only after relevant studies within a defined scope have been reviewed and evidence answering the conditions is insufficient. Not applied across the board in this review
Not applicable
A specific exception based on applicability conditions. Not a replacement status for unread materials
Conflicting data
Used when compared data for the same question, time point and analysis are difficult to reconcile. Not assigned merely because review estimates differ
Met
All required conditions can be explained using locations in original sources. Not synonymous with established efficacy

Change history

2026-10-07 · Public page/material version 1.0

Public-facing pages and materials were prepared from the existing 22 items. No new clinical search, verification-status changes or scoring were performed.

The stored-material review date (2026-10-04) and original evidence cut-off (2026-07-24) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which population with type 2 diabetes does the effect apply to?

Current findings
The stored summary identifies the population as people with type 2 diabetes. Trial-specific diagnoses, ages, baseline HbA1c and settings could not be verified from that summary.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
The named target population is verified, but trial-specific conditions needed to establish population alignment are unverified.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Obtain trial-specific diagnoses, ages, baseline HbA1c, disease duration, care settings and inclusion/exclusion criteria
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Prespecified stratified comparative trials including populations with different representativeness; first obtain tables of the included trials' characteristics
Remaining uncertainty
Who the findings apply to, and differences between deficient and non-deficient participants
Conditions for verification
Identify each trial's population, diagnoses and baseline characteristics, and explain matches or differences with the selected claim using locations in the original paper
Why this condition is needed
The broad label 'type 2 diabetes' does not establish that the target populations are equivalent.
Application exceptions
For mixed populations, separate results or documentation of the population mix and indirectness are acceptable. Other types of diabetes require a separate question.
Referenced methods
M03 §3.2.1

Related sources S01 S02 S03

N02 · What was actually administered?

Current findings
The stored summary names oral tablets or capsules and states that superiority of a specific formulation has not been established. Each trial's chemical form, combination ingredients and product remain unverified.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
The route specified in the claim is verified, but original materials needed to match each trial's formulation and ingredients are insufficient.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Verify the chemical form of vitamin C, single ingredient versus combination, tablet versus capsule, oral route, product and content
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Obtain product analyses and manufacturing/content records; superiority of a particular formulation requires a direct comparative trial
Remaining uncertainty
The contribution of vitamin C alone and equivalence between products
Conditions for verification
Verify each trial's actual ingredients, route, formulation and control ingredients, while retaining unverified details as unverified
Why this condition is needed
Needed to avoid attributing effects from other formulations, routes or added ingredients to oral vitamin C.
Application exceptions
Combination products may contribute if shared ingredients and between-group differences can be separated. Intravenous preparations and foods require separate comparisons.
Referenced methods
M03 §3.2.2–3.2.3

Related sources S01 S03

N03 · Which dose is the efficacy question about?

Current findings
The overall review's dose range of 200–3,000 mg/day is preserved. Dose, adherence, diet and baseline vitamin C status in each HbA1c trial remain unverified.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Do not assume that the overall review's range represents identical conditions in the trials contributing to HbA1c.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Distinguish daily prescribed dose, dosing frequency, actual intake, adherence, baseline diet and vitamin C status
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Comparative trials with prespecified exposure measurement and adherence tracking; effect-modification analyses by baseline status
Remaining uncertainty
The exposure at which the results were observed
Conditions for verification
Link dose, actual exposure, verification methods and duration for each trial contributing to the HbA1c analysis
Why this condition is needed
If nominal dose differs from actual exposure, applicability and dose interpretation change.
Application exceptions
When baseline deficiency information is absent, retain studies of the overall effect and leave only deficiency-specific applicability unverified.
Referenced methods
M03 §3.2.2; M15 §15.2.4

Related sources S01 S03

N04 · Lower than what comparator?

Current findings
The stored review summary does not provide each trial's comparator details or the group order used to calculate effects. The existing explanation describes a between-group mean difference, but original trial and synthesis tables were not checked.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
The actual comparison is not established because original descriptions of the comparison were not obtained.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Specify the actual placebo, no-treatment, usual-care or active comparator and fix the group order used to calculate the effect
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Trials explicitly describing placebo/no added vitamin C and shared treatment, or original descriptions of existing comparators
Remaining uncertainty
Mixing placebo, usual-care and active comparisons
Conditions for verification
Verify each trial's control conditions, group order and rationale for inclusion in the synthesis
Why this condition is needed
A different comparator means a different question, even when the numerical result is the same.
Application exceptions
Retain active-comparator results, but present them separately from the main question comparing against no added vitamin C.
Referenced methods
M03 §3.2.3

Related sources S01 S02 S03

N05 · Can the contribution of added vitamin C be separated?

Current findings
Each group's concomitant diabetes treatment, medication adjustments, diet/exercise and other supplements could not be verified from the stored review summary.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
General advice against replacing medication is not an experimental record establishing identical treatment in both groups.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Verify shared diabetes treatment, medication adjustments, diet, exercise, other supplements and changes in both groups
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Add-on treatment trials with prespecified records of shared treatment, adjustment rules and rescue treatment
Remaining uncertainty
The contribution of treatment differences other than vitamin C
Conditions for verification
Link baseline and follow-up concomitant treatments/changes, between-group differences and how they were handled
Why this condition is needed
Check whether differences in other treatments contribute to the observed difference.
Application exceptions
Do not require completely identical treatment. If treatment changes, review balance, analysis and alignment with the effect of interest.
Referenced methods
M03 §3.2.3; M08 §8.2.2–8.2.3

Related sources S01 S03

N06 · Can intervention effects be distinguished from chance and confounding?

Current findings
The reports are labelled systematic reviews/meta-analyses of RCTs. Randomization, concealment and baseline balance in the original trials are unverified.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Distinguish the existence of a study-design label from a result-specific assessment of bias.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Randomization methods, allocation concealment, baseline balance and result-specific risk-of-bias information from comparative trials
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Preregistered comparative trials with appropriate randomization, concealment and result analyses; first obtain the original methods
Remaining uncertainty
Differences arising during allocation
Conditions for verification
Obtain original evidence of the actual design, randomization/concealment and relevant baseline differences, and discuss their effect on results
Why this condition is needed
The label 'randomized' alone does not resolve risk-of-bias concerns.
Application exceptions
Also record and use non-randomized studies as supporting evidence. Judgments must fit parallel, crossover or cluster designs. A formal RoB 2 assessment is outside this review's scope.
Referenced methods
M08 §8.1–8.2.3

Related sources S01 S03

N07 · Is this the effect of assignment or the effect of adhering to treatment?

Current findings
The stored summary records a mean reduction and a WMD. Mixing final values with changes, adjustment, ITT/PP, and parallel/crossover/cluster designs remain unverified.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Do not reinterpret −0.54 as a within-group change.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Distinguish ITT/PP, analysis populations, adjustment variables, final values versus changes, and handling of crossover/cluster designs
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Comparative trials or reanalysis materials providing a prespecified analysis plan and necessary correlation, period and cluster information
Remaining uncertainty
Alignment between the effect of interest and the actual analysis
Conditions for verification
Verify agreement or differences between the effect of interest, the actual analysis and the effect used in the synthesis
Why this condition is needed
Needed to avoid combining different effects and analyses as if they were the same result.
Application exceptions
Crossover/cluster requirements are marked not applicable or handled separately only after the design is verified.
Referenced methods
M08 §8.2.2; M15 §15.3.1

Related sources S01 S03

N08 · Who was lost to follow-up?

Current findings
1,133/1,247 are recorded as outcome-specific synthesis samples for HbA1c. Group-specific allocation/completion/analysis numbers and dropout reasons are not recorded at this location.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Not reported in the stored summary. This does not establish that the full paper failed to report it.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Group-specific numbers allocated, completing follow-up, measured and analysed; reasons for dropout, handling of missing data and sensitivity analyses
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Trials tracking dropout causes and follow-up with sensitivity analyses under different assumptions; obtain existing flow diagrams and analysis materials
Remaining uncertainty
How much missing data and dropout could alter the result
Conditions for verification
Link outcome- and time-specific denominators, missingness, handling methods and results under different assumptions
Why this condition is needed
Review the possibility that missing data changed the observed result.
Application exceptions
Do not use an arbitrary universal dropout-rate threshold. Examine causes of missingness and their relationship to the outcome.
Referenced methods
M08 Table 8.2.a

Related sources S01 S03

N09 · Are the HbA1c measurements comparable?

Current findings
HbA1c units in percentage points and cautions about glucose-meter/some assay interference are recorded. Trial-specific HbA1c assays, blinding and interference remain unverified.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
A glucose-meter caution is not evidence that the HbA1c results are erroneous.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Verify HbA1c assay methods, units, blood-sampling times, assay interference/red-cell limitations and assessor blinding
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Trials reporting assay methods, interference validation and blood-sampling rules; analytical method comparisons where needed
Remaining uncertainty
Distinguishing differences in measurement methods from actual changes
Conditions for verification
Verify each trial's HbA1c methods, units, visits and measurement limitations. Distinguish percentage points from relative percentages
Why this condition is needed
Needed to distinguish measurement differences from actual changes.
Application exceptions
Do not generalize glucose-meter interference to all HbA1c assays. Review each assay method separately.
Referenced methods
M08 Table 8.2.a; M03 §3.2.4

Related sources S01 S03

N10 · Does the observation period fit the question?

Current findings
The stored summary describes an overall review range of 2 weeks–1 year, mostly less than 6 months. Durations of the individual trials contributing to HbA1c are unverified.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Do not transfer the overall review's duration range to each individual HbA1c trial.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Record treatment, measurement and follow-up periods separately, with evidence supporting the time frame used to interpret HbA1c changes
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Trials scheduling visits based on the outcome's time characteristics; official original assay references supporting duration criteria require follow-up checking
Remaining uncertainty
Outcome timing and criteria for an appropriate follow-up period
Conditions for verification
Specify the timeline of each contributing trial, the questions that timeline can answer and its limitations
Why this condition is needed
Short-term observation and sustained effects are different questions.
Application exceptions
Do not adopt an arbitrary minimum number of weeks. An appropriate duration is undetermined from these materials alone.
Referenced methods
M03 §3.2.2–3.2.4

Related sources S01 S03

N11 · Exactly what difference was observed?

Current findings
S01 −0.54 percentage points (95% CI −0.90 to −0.17) and S03 WMD −0.51 percentage points (95% CI −0.81 to −0.20) are preserved. S02 restates −0.54.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
The stored locations of values and units are verified, but group order, analysis/time points and attribution to original paper tables are unverified.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Link effect estimates, measures, units, group order, confidence intervals, time points, denominators and adjustment to original materials
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Obtain original trial result tables/supplements and recheck the original numbers; define the unit of analysis before a new synthesis
Remaining uncertainty
Definition of between-group results, synthesis models and included values
Conditions for verification
Make analysis attribution traceable so that distinct results are not mistaken for the same effect
Why this condition is needed
Within-group changes, between-group differences and pooled estimates are different results.
Application exceptions
Retain synthesis summaries as results, while distinguishing them from direct results of original trials.
Referenced methods
M15 §15.3.1–15.3.3

Related sources S01 S02 S03

N12 · What conclusions does the interval allow?

Current findings
Outcome-specific HbA1c CIs and samples are available. The stored summary mentions some clinical-relevance thresholds, but contains no verified numerical threshold or source supporting its application.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Precision sufficiency is not judged because no new importance threshold has been invented.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Link outcome-specific samples, variance and effect intervals to a justified important difference
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Trials with sample sizes based on important-difference, variance and dropout assumptions; first agree on the threshold and obtain existing variance information
Remaining uncertainty
Whether an important difference is excluded or allowed, and assumptions used to design the sample
Conditions for verification
Compare the effects the CI excludes or allows—important effects, small effects or no difference—with an evidence-based threshold
Why this condition is needed
Study or participant counts alone cannot establish sufficiency, and statistical significance does not establish efficacy.
Application exceptions
If a clinical-importance threshold is absent, leave it undetermined. Do not impose an arbitrary minimum sample or trial count.
Referenced methods
M15 §15.3.1–15.3.3

Related sources S01 S03

N13 · Can all prespecified results be examined?

Current findings
Bibliographic records in the stored materials mainly concern reviews. Original trial registrations, protocols, SAPs and comparisons of prespecified versus reported HbA1c analyses were not verified from these materials.
Verification status
Review incomplete
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Registrations/plans were neither obtained nor searched in this review. Lack of registration or selective reporting is not established.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Compare registration, protocol and analysis plans with reported HbA1c time points, analyses and reasons for changes
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Trials publishing preregistration, protocols/SAPs and all results, or retrieval of existing registrations/supplements
Remaining uncertainty
Whether outcomes, analyses and time points were prespecified
Conditions for verification
Compare prespecified and reported outcomes, analyses and time points, explaining changes or why comparison is impossible
Why this condition is needed
Examine whether an analysis was selected because its results were favourable.
Application exceptions
Retain the study's existence and results even if registration is absent or private. Do not turn an unverified status into confirmed selective reporting.
Referenced methods
M08 Table 8.2.a; M04 §4.6.3

Related sources S01 S03

N14 · Do three review papers represent independent replication?

Current findings
Bibliographic identities exist for three review reports. The acquired summaries contain no original-trial/related-report family table or review-overlap table.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Do not add original trial counts as 16+18 or participants as 1,133+1,247.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Link original trials, registrations, related reports and review inclusion tables into study families, recording overlap
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Obtain included-trial/registration lists and compare duplicates; then conduct independent replication in a different recruited population
Remaining uncertainty
Unique trials/participants and independent replication
Conditions for verification
Trace report → original trial → inclusion in each review, and identify matching or unresolved identities
Why this condition is needed
The same participants or trial must not be counted more than once.
Application exceptions
Retain unresolved study families under provisional identities. Unique trial and participant counts remain undetermined.
Referenced methods
M04 §4.6.1–4.6.2

Related sources S01 S02 S03

N15 · Are results consistent under different conditions?

Current findings
S03 I²=90.4% is recorded in the stored summary. Trial-specific opposing/no-difference/positive HbA1c values are unverified. Non-significant results and limitations for other outcomes are also preserved in the original record.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Similar directions of two pooled averages do not verify independent replication or consistent effects in individual trials.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Record trial-specific opposing, no-difference and positive results, condition differences, heterogeneity and prespecified subgroups
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Independent multicentre replication under standardized conditions; test prespecified hypotheses about baseline status and dose
Remaining uncertainty
Causes of inconsistency, locations of opposing results and reproducibility
Conditions for verification
Preserve the distribution of unique trial results, explanations of condition differences/inconsistency and uncertainty
Why this condition is needed
One pooled average does not guarantee results in every population and setting.
Application exceptions
Between-study comparison may be not applicable for a single study family, but NA is not assigned here because study families remain unresolved.
Referenced methods
M03 §3.2.1; M15 §15.3.1

Related sources S01 S02 S03

N16 · Is a higher dose better?

Current findings
The stored summary states that a standard diabetes dose and superiority of particular formulations are undetermined. Direct dose-comparison results could not be verified from the stored summary.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Further searching is needed to establish whether dose studies exist beyond these stored materials.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Direct dose comparisons, exposure/dose response, and joint observation of benefits and harms
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Randomized dose comparisons using the same formulation and shared treatment. Determine sample sizes and doses after reviewing the evidence
Remaining uncertainty
Dose selection considering benefits and harms together
Conditions for verification
Dose differences within the same comparison framework, or dose-response evidence explicitly describing confounding limitations
Why this condition is needed
Dose differences across trials may be confounded by differences in populations and durations.
Application exceptions
The main HbA1c-change question can be retained without claiming dose superiority.
Referenced methods
M03 §3.2.2; Chamgap's own dose-study design proposal

Related sources S01 S03

N17 · Does the effect persist long term or after stopping treatment?

Current findings
The limitation that most studies are short term is preserved. Post-treatment persistence, long-term medication changes and fixed extension follow-up results are unverified in the acquired summaries.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
A duration range including 1 year does not by itself verify long-term persistence or persistence after stopping treatment.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Verify long-term exposure, post-treatment visits, medication changes and HbA1c trajectories
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Comparative trials/follow-up studies with prespecified long-term extensions and post-treatment follow-up. Duration is undetermined
Remaining uncertainty
Long-term maintenance and the effects of treatment changes
Conditions for verification
Long-term comparative results with timelines, treatment continuation/discontinuation and loss to follow-up
Why this condition is needed
A change at the end of treatment differs from a sustained effect.
Application exceptions
Do not remove short-term studies as ineligible. Leave persistence separately unverified.
Referenced methods
M03 §3.2.2; Chamgap's own persistence-study design proposal

Related sources S01 S03

N18 · What harms were observed in the same population at the same dose?

Current findings
The existing summary records limited safety data and gastrointestinal/oxalate cautions. Group-specific event counts, denominators and durations in this population at these doses are unverified.
Verification status
Partly verified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Separate general cautions from events observed in trials. Do not record non-reporting as zero events.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Verify group-specific harm definitions, collection methods, event/person counts, denominators, exposure periods and discontinuations
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Obtain comparative trials/safety reports documenting both prespecified harm collection and unanticipated harms
Remaining uncertainty
Actual harm frequency and collection methods
Conditions for verification
Distinguish events in both groups, observation periods, denominators, collection methods and non-reporting
Why this condition is needed
Non-reporting cannot be interpreted as zero events or established safety.
Application exceptions
Retain efficacy results even when harms are not reported in an efficacy study. Present safety separately.
Referenced methods
M19 §19.1.2–19.2.4

Related sources S02 S04

N19 · What about harms outside short trials and vulnerable populations?

Current findings
The stored summary cautions about kidney disease/stone histories and iron overload. Long-term exposure and absolute risks in specific populations are unverified in these materials.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
The existence of a caution group is not a numerical risk estimate or evidence of no efficacy.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Exposure, comparisons, occurrence and long-term harm data in existing caution groups, including people with kidney disease/stone histories or iron overload
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Long-term cohorts/registries with denominators, exposure and appropriate comparators; special-population data require separate searching
Remaining uncertainty
Long-term and rare harms, and risks in vulnerable populations
Conditions for verification
Verify design-specific event definitions, exposure, comparisons/confounding, denominators, durations and population-applicability limitations
Why this condition is needed
The restricted populations and durations of efficacy trials may not capture rare harms.
Application exceptions
Also preserve observational studies, registries and case signals. Without control of confounding and denominators, do not establish incidence rates or causality.
Referenced methods
M19 §19.1.2, §19.2.2–19.2.4

Related sources S04

N20 · Is the effect greater in deficient participants or particular populations?

Current findings
The stored summary describes possible differences by low baseline vitamin C, dose and duration. Prespecified subgroup and interaction evidence is unverified.
Verification status
Unverified
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Do not upgrade a hypothesis to verified efficacy in a particular population.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Baseline vitamin C, HbA1c, medication/disease characteristics, prespecified effect-modification hypotheses and interactions
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Prespecified stratified trials or agreed individual-participant-data analyses. Label subgroups not defined in advance as exploratory
Remaining uncertainty
Effect differences by deficiency, disease severity and special population
Conditions for verification
Verify prespecified hypotheses and definitions, subgroup samples/estimates, interactions and precision
Why this condition is needed
Needed to avoid extending an overall average to a particular population.
Application exceptions
Pregnancy, children and other types of diabetes are not automatic extensions of this claim.
Referenced methods
M03 §3.2.1; Chamgap's own effect-modification proposal

Related sources S01 S03

N21 · What might the current record have missed?

Current findings
The existing evidence cut-off field is 2026-07-24. On 2026-10-04, only stored materials and methodology were checked; no new clinical search or correction/retraction checks were performed.
Verification status
Review incomplete
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
This case did not review the entire current clinical literature or its latest status. The existence and accessibility of materials beyond papers are also unverified.
Reason for missing information
Not recorded in the stored summary / review of original papers incomplete. This does not establish that the original papers failed to report the information or were inaccessible
Required materials and conditions
Search scope/dates, inclusion/exclusion, registrations/unpublished studies, corrections/retractions, and material-specific access/reading histories
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
In an authorized follow-up, search and select new literature/registrations/publication-status information and record access. This was not performed here
Remaining uncertainty
Missing/unpublished/new studies, publication status and access scope
Conditions for verification
Record the scope in which evidence is absent or unverified, by date and material type
Why this condition is needed
The existence of a stored summary does not mean the entire current literature has been checked.
Application exceptions
No new clinical search was performed. Only the currently preserved scope applies.
Referenced methods
M04 §4.5, §4.6.3

Related sources S01 S02 S03 S04

N22 · Does a change in HbA1c directly establish benefits for complications?

Current findings
The selected question concerns numerical HbA1c change. Existing separate subclaims describe benefits for complications/mortality as unestablished. Those findings were not reassessed here.
Verification status
Not applicable (as a mandatory condition for the selected outcome)
Materials actually read
Stored existing review summaries were read on 2026-10-04. Full papers, supplements, registrations, plans and original data were not read.
Why unverified
Clinical-event trials are not required for the HbA1c question itself. Extending to benefits for complications requires separate conditions.
Reason for missing information
Not applicable with an explicit application exception
Required materials and conditions
Questions about complications, quality of life or mortality require separate comparative results, events and durations for those outcomes
Materials to obtain first
First obtain and compare the necessary original materials, including existing papers, supplements and tables of included trials.
Further research
Long-term comparative trials based on clinical events, with a separately defined question. This is not a new claim or search in this case
Remaining uncertainty
Questions about complications, mortality and quality of life are outside this scope and require further searching
Conditions for verification
Identify the separate clinical question/outcome and direct evidence. Do not automatically extend HbA1c findings
Why this condition is needed
A boundary distinguishing questions about biomarkers from questions about clinical events.
Application exceptions
Do not require clinical-event trials as a mandatory condition for the selected question about numerical HbA1c change itself.
Referenced methods
M03 §3.2.4; Chamgap's own boundary for extended claims

Related sources S01 S03